BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 23653048)

  • 41. Potential of the Akt inhibitor LY294005 to antagonize the efficacy of Cisplatin against HCT116 tumor cells in a DNA mismatch repair-dependent manner.
    Fedier A; Erdmann R; Boulikas T; Fink D
    Int J Oncol; 2006 Nov; 29(5):1303-10. PubMed ID: 17016665
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Presence of MLH1 protein aggravates the potential of the HSP90 inhibitor radicicol to sensitize tumor cells to cisplatin.
    Fedier A; Stuedli A; Fink D
    Int J Oncol; 2005 Dec; 27(6):1697-705. PubMed ID: 16273226
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effects of hyperthermia on Hsp27 (HSPB1), Hsp72 (HSPA1A) and DNA repair proteins hMLH1 and hMSH2 in human colorectal cancer hMLH1-deficient and hMLH1-proficient cell lines.
    Nadin SB; Cuello-Carrión FD; Sottile ML; Ciocca DR; Vargas-Roig LM
    Int J Hyperthermia; 2012; 28(3):191-201. PubMed ID: 22515340
    [TBL] [Abstract][Full Text] [Related]  

  • 44. DNA damage-induced expression of p53 suppresses mitotic checkpoint kinase hMps1: the lack of this suppression in p53MUT cells contributes to apoptosis.
    Bhonde MR; Hanski ML; Budczies J; Cao M; Gillissen B; Moorthy D; Simonetta F; Scherübl H; Truss M; Hagemeier C; Mewes HW; Daniel PT; Zeitz M; Hanski C
    J Biol Chem; 2006 Mar; 281(13):8675-85. PubMed ID: 16446370
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Functional effects of the MLH1-93G>A polymorphism on MLH1/EPM2AIP1 promoter activity.
    Perera S; Mrkonjic M; Rawson JB; Bapat B
    Oncol Rep; 2011 Mar; 25(3):809-15. PubMed ID: 21206982
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Epigenetic inactivation of a cluster of genes flanking MLH1 in microsatellite-unstable colorectal cancer.
    Hitchins MP; Lin VA; Buckle A; Cheong K; Halani N; Ku S; Kwok CT; Packham D; Suter CM; Meagher A; Stirzaker C; Clark S; Hawkins NJ; Ward RL
    Cancer Res; 2007 Oct; 67(19):9107-16. PubMed ID: 17909015
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Curcumin suppresses multiple DNA damage response pathways and has potency as a sensitizer to PARP inhibitor.
    Ogiwara H; Ui A; Shiotani B; Zou L; Yasui A; Kohno T
    Carcinogenesis; 2013 Nov; 34(11):2486-97. PubMed ID: 23825154
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Decreased expression of hMLH1 correlates with reduced 5-fluorouracil-mediated apoptosis in colon cancer cells.
    Fujita H; Kato J; Horii J; Harada K; Hiraoka S; Shiraha H; Sakaguchi K; Shiratori Y
    Oncol Rep; 2007 Nov; 18(5):1129-37. PubMed ID: 17914563
    [TBL] [Abstract][Full Text] [Related]  

  • 49. UCN-01 inhibits p53 up-regulation and abrogates gamma-radiation-induced G(2)-M checkpoint independently of p53 by targeting both of the checkpoint kinases, Chk2 and Chk1.
    Yu Q; La Rose J; Zhang H; Takemura H; Kohn KW; Pommier Y
    Cancer Res; 2002 Oct; 62(20):5743-8. PubMed ID: 12384533
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Augmentation of apoptosis and tumor regression by flavopiridol in the presence of CPT-11 in Hct116 colon cancer monolayers and xenografts.
    Motwani M; Jung C; Sirotnak FM; She Y; Shah MA; Gonen M; Schwartz GK
    Clin Cancer Res; 2001 Dec; 7(12):4209-19. PubMed ID: 11751522
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antisense anti-MDM2 mixed-backbone oligonucleotides enhance therapeutic efficacy of topoisomerase I inhibitor irinotecan in nude mice bearing human cancer xenografts: In vivo activity and mechanisms.
    Wang H; Wang S; Nan L; Yu D; Agrawal S; Zhang R
    Int J Oncol; 2002 Apr; 20(4):745-52. PubMed ID: 11894120
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib ("Iressa") and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cells.
    Koizumi F; Kanzawa F; Ueda Y; Koh Y; Tsukiyama S; Taguchi F; Tamura T; Saijo N; Nishio K
    Int J Cancer; 2004 Jan; 108(3):464-72. PubMed ID: 14648715
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Identification of novel, in vivo active Chk1 inhibitors utilizing structure guided drug design.
    Massey AJ; Stokes S; Browne H; Foloppe N; Fiumana A; Scrace S; Fallowfield M; Bedford S; Webb P; Baker L; Christie M; Drysdale MJ; Wood M
    Oncotarget; 2015 Nov; 6(34):35797-812. PubMed ID: 26437226
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin.
    Zeghari-Squalli N; Raymond E; Cvitkovic E; Goldwasser F
    Clin Cancer Res; 1999 May; 5(5):1189-96. PubMed ID: 10353756
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Sensitization of colorectal cancer to irinotecan therapy by PARP inhibitor rucaparib.
    Augustine T; Maitra R; Zhang J; Nayak J; Goel S
    Invest New Drugs; 2019 Oct; 37(5):948-960. PubMed ID: 30612311
    [TBL] [Abstract][Full Text] [Related]  

  • 56. DNA mismatch repair gene MLH1 induces apoptosis in prostate cancer cells.
    Fukuhara S; Chang I; Mitsui Y; Chiyomaru T; Yamamura S; Majid S; Saini S; Hirata H; Deng G; Gill A; Wong DK; Shiina H; Nonomura N; Dahiya R; Tanaka Y
    Oncotarget; 2014 Nov; 5(22):11297-307. PubMed ID: 25526032
    [TBL] [Abstract][Full Text] [Related]  

  • 57. UV light-induced degradation of RNA polymerase II is dependent on the Cockayne's syndrome A and B proteins but not p53 or MLH1.
    McKay BC; Chen F; Clarke ST; Wiggin HE; Harley LM; Ljungman M
    Mutat Res; 2001 Mar; 485(2):93-105. PubMed ID: 11182541
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Differential cellular responses to prolonged LDR-IR in MLH1-proficient and MLH1-deficient colorectal cancer HCT116 cells.
    Yan T; Seo Y; Kinsella TJ
    Clin Cancer Res; 2009 Nov; 15(22):6912-20. PubMed ID: 19861440
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Carnosol induces apoptosis through generation of ROS and inactivation of STAT3 signaling in human colon cancer HCT116 cells.
    Park KW; Kundu J; Chae IG; Kim DH; Yu MH; Kundu JK; Chun KS
    Int J Oncol; 2014 Apr; 44(4):1309-15. PubMed ID: 24481553
    [TBL] [Abstract][Full Text] [Related]  

  • 60. PARP-1-dependent RND1 transcription induced by topoisomerase I cleavage complexes confers cellular resistance to camptothecin.
    Mouly L; Mamouni K; Gence R; Cristini A; Cherier J; Castinel A; Legrand M; Favre G; Sordet O; Monferran S
    Cell Death Dis; 2018 Sep; 9(9):931. PubMed ID: 30209297
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.